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Pancreatic b-cellNur77 is a stress sensor in pancreatic b-cells, which negatively regulates glucose-stimulated insulin
secretion. We recently showed that a lipotoxic shock caused by exposure of b-cells to the saturated
fatty acid palmitate strongly increases Nur77 expression. Here, using dual luciferase reporter assays
and Nur77 promoter deletion constructs, we identiﬁed a regulatory cassette between 1534 and
1512 bp upstream from the translational start site mediating Nur77 promoter activation in
response to palmitate exposure. Chromatin immunoprecipitation, transient transfection and
siRNA-mediated knockdown assays revealed that palmitate induced Nur77 promoter activation
involves Sp1 recruitment and ZBP89 release from the gene promoter.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Peripheral insulin resistance combined with pancreatic b-cell
dysfunction leads to type 2 diabetes, which is favored by genetic
backgrounds and environmental factors. Hyperglycemia and
hyperlipidemia induce additional damages or toxic effects in b-
cells. Notably, the increased release of free fatty acids (FFAs) con-
tributes to the deterioration of b-cell functions [1,2] and plays a
pathogenic role in the early stages of this disease. Chronically ele-
vated FFA levels impair glucose-stimulated insulin secretion (GSIS)
and induce apoptosis of insulin-secreting b-cells [3,4]. Several
in vitro studies using isolated islets showed lowered insulin gene
expression and impaired GSIS after exposure to FFAs [5,6]. How-
ever, the mechanism(s) responsible for palmitate-induced b-cell
defect are incompletely understood. Triglyceride storage, reactive
oxygen species production, dysregulation of the glucose metabolic
pathway [7] and GPR40 FFA membrane receptor activation [8] are
involved in FFA-induced GSIS inhibition. Notably, palmitate-
derived ceramide alters pancreatic and duodenal homeobox-1(PDX-1) subcellular localization and MafA expression, which play
a key role in activation of the insulin gene [9]. More recently,
[10] identiﬁed by a proteomic approach several pathways respon-
sible for palmitate-induced b-cell dysfunction and death. Palmitate
induces b-cell dysfunction by triggering endoplasmic reticulum
stress and generation of harmful metabolites during triglyceride
synthesis, hampering insulin maturation and altering intracellular
trafﬁcking.
The nuclear orphan receptor (NR4A) protein subclass contains
three members (Nur77/NR4A1; Nurr1/NR4A2 and Nor1/NR4A3)
implicated in multiple cellular and metabolic functions in the liver,
skeletal muscle, brain, heart and adipose tissues [11]. These tran-
scription factors are known to be rapidly and transiently induced
by a diverse range of signals including extracellular stresses such
as lipotoxic fatty acids, glucose or proinﬂammatory cytokines.
The transcriptional activity of these receptors is primarily regu-
lated through altered expression and/or posttranslational modiﬁ-
cation. Our recent study revealed a previously unrecognized
function for Nur77 as a lipotoxicity sensor regulating glucose-
induced insulin secretion in b-cells [12]. As the most common sat-
urated nonesteriﬁed fatty acid in human plasma, palmitate has
been used to evaluate the contribution of NR4As to b-cell biology.
Functional interaction of Nur77 with FOXO1 revealed a mechanis-
tic basis for the Nur77-mediated inhibition of insulin biosynthesis
3884 C. Mazuy et al. / FEBS Letters 587 (2013) 3883–3890though impaired mafA expression. However, how Nur77 expres-
sion is induced by a lipotoxic stress has not been characterized.
Thus, we aimed to identify how fatty acids induce Nur77 expres-
sion in b-cells. In this study, we show that palmitate-mediated
induction of Nur77 gene expression involves Sp1 recruitment to-
gether with ZBP89 release from the gene promoter potentially
through direct competitive binding to overlapping sites.
2. Materials and methods
2.1. Reagents
Sodium palmitate (P9767) and oleate (O7501) were from Sigma
(St. Louis, MO). Stock solutions (100 mM) of sodium palmitate and
oleate were prepared in ultrapure water and then were added to
10% FA-free BSA to a 5 mM ﬁnal concentration and ﬁltered.
2.2. Cell preparation
MIN6 cells were grown in 75-cm2 ﬂasks with 20 ml of Dul-
becco’s modiﬁed Eagle’s medium (DMEM, GIBCO-Invitrogen) con-
taining 25 mM glucose, 50 lM b-mercaptoethanol, 110 U/ml
penicillin, 110 U/ml streptomycin supplemented with 10% heat
inactivated fetal bovine serum (growth medium) at 37 C in a
humidiﬁed atmosphere of 95% air/5% CO2.0
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Fig. 1. Isolation of the activating region of Nur77 using promoter deletion constructs. D
constructs shortened stepwise from upstream. (A) Palmitate activation (24 h) on Nur7
promoter fragments from 2000 to 1445 bp were used for sub-localization. Quantiﬁc
test).2.3. Cloning of the Nur77 (2000/+1) promoter luciferase construct
The Nur77 promoter (2000/+1) was ampliﬁed from murin
genomic DNA (http://www.informatics.jax.org; ID: 1352454) and
cloned into the pGL3TK-luc vector. The following primers were
used: 50-AGTCGCTAGCGGTGGAGAGATAAAATGGGG-30 and 50-
AGTCCTCGAGTCCTGCACTGGGGCTCCCCT-30.
2.4. Site directed mutagenesis
The Nur77 promoter construct was modiﬁed using a site-direc-
ted mutagenesis kit (QuickChange, Stratagene). Primers were de-
signed to delete 1525–1523 bp from the sequence of Nur77
(2000/+1) promoter according to the manufacturer’s recommen-
dations (http:/labtools.stratagene.com). Mutagenesis was per-
formed using primers 50-GAAATAGCAGGCTGGTTGGTAAGGGG
GGTCTTTTGTGGTGA-30 and 50-TCACAACAAAAGACCCCCCTTACCA
ACCAGCCTGCTATTTC-30.
2.5. Dual luciferase reporter assay
MIN6 cells were seeded in 48-well plates and transfected 48 h
later with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) using
0.4 lg promoter reporter constructs and/or empty plasmid vector
(pGL3TK-luc) and/or varying quantities of Sp1 or ZBP89 expression**
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Fig. 2. Veriﬁcation of ZBP89 and Sp1 activation of mutated Nur77 promoter regulatory cassette in MIN6 cells. (A) ZBP89 binding site was mutated using site-directed
mutagenesis as described in experimental procedures. (B) For dual luciferase reporter assay, MIN6 cells were transfected with the ZBP89 mutated binding site within the
Nur77 promoter regulatory cassette located on the 1525 bp-Nur77 pGL3TK construct. Quantiﬁcation represents ﬁve independent experiments. Data are means ± S.D.
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Fig. 3. Veriﬁcation of ZBP89 and Sp1 bindings at their response elements of the Nur77 promoter by chromatin immunoprecipitation assays. MIN6 cells were chemically cross-
linked with formaldehyde. Chromatin was extracted, fragmented and immunoprecipitated with ZBP89, Sp1 and RNApol II antibodies. The postulated binding regions of the
Nur77 promoter were ampliﬁed by QPCR and results were normalized to myoglobin. Results are plotted as the fold enrichment over background.
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was replaced 5 h later by fresh growth medium containing palmi-
tate or oleate (0.4 mM). Luciferase activity was measured (Lucifer-
ase assay system; Promega Corp., Madison, WI) with a Victor Light
(Perkin Helmer) plate reader and normalized to cellular DNA.
Transfection experiments were done at least three times in
triplicate.
2.6. RT-QPCR analysis
Total RNA was extracted using RNeasy (QIAGEN, Chatsworth,
CA) according to the manufacturer’s instructions. DNase I-treated
total RNA was reverse transcribed using High-Capacity cDNA ar-
chive kit (Applied Biosystems, Foster City, CA). For Nur77 gene
expression, cDNA were analysed using TaqMan Gene Expression
Assays as recommended by the manufacturer. Relative geneexpression was calculated by the DDCt method. Final results were
expressed as the fold difference in gene expression normalized to
18S rRNA and relative to control conditions. For ZBP89 and Sp1
gene expression, QPCR were carried out using SyberGreen-based
chemistry. Primers used were: 50-TTCTGCAGCAGGCTTTGGAC-30
and 50-TGGGCATGGCTGAATAGACT-30 for ZBP89 and 50-TCAGAACC
CACAAGCCCAGA-30 and 50-AGGAATGGAGGCAGCTGAGG-30 for Sp1.
2.7. Cellular extract preparation and western blotting
The following antibodies were used: anti-ZBP89 (Sc-48811,
Santa-Cruz Biotech.), anti-Sp1 (Sc-14027, Santa-Cruz Biotech.)
and anti-HSP a/b (Sc-7947). Approximatively 2  107 cells were
lysed in cell lysis buffer containing 20 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1% Triton, 2.5 mM sodium pyrophos-
phate, 1 mM b-glycerophosphate, 1 mMNa3VO4, 1 lg/ml leupeptin
3886 C. Mazuy et al. / FEBS Letters 587 (2013) 3883–3890and 1 lM PMSF. Proteins were boiled 5 min in 2 Laemmli buffer,
separated by 10% SDS–PAGE and revealed by Western blotting
using SuperSignal West Dura Extended Duration Substrate (Ther-
moScientiﬁc, Illkirch, France). Images were acquired on a G-BOX
(Syngene, Cambridge, UK) and quantiﬁcation were performed
using ImageQuant software.
2.8. Chromatin immunoprecipitation assays
MIN6 cells were seeded in 10-cm dishes and incubated with
0.4 mM palmitate for 24 h. Chromatin immunoprecipitation (ChIP)
assays were then performed as described by Sérandour [13]. Anti-
bodies used in chromatin immunoprecipitation were raised against
ZBP89 (sc-48811), Sp1 (sc-14027) and RNA Pol II (sc-899) from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Primers for ChiP
PCR were 50-TTCTGCAGCAGGCTTTGGAC-30, 50-TGGGCATGGCTG
CATAGACT-50 for ZBP89 and 50-TCAGAACCCACAAGCCCAGA-30, 50-
AGGAATGGAGGCAGCTGAGG-30 for Sp1. For Nur77-TSS, primers
for ChiP PCR were 50-CCCTTGTATGGCCAAAGCTC-30, 50-CATCTTA
AGCGCTCCGTGAC-30.ZBP89 
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Fig. 4. (A and B) Conﬁrmation of ZBP89 knockdown using MIN6 cells treated with 0.4 mM
mRNA and qPCR analysis (A) or Western blot analysis (B). (C) Same cells were used to qu
independent experiments. Data are means ± S.D.2.9. Gene knockdown
MIN6 cells were transfected with siRNA directed against ZBP89
(sc-38640) or Sp1 (sc-29488) or with a negative control siRNA
using Lipofectamine according to the manufacturer’s instructions
(Santa Cruz, CA). After 5 h, the transfection medium was replaced
with growth medium, and the cells were further cultured with
0.4 mM palmitate for 24 h. The knockdown efﬁciency was veriﬁed
by QPCR. Oligonucleotides used for ZBP89 and Sp1 were respec-
tively 50-TTCTGCAGCAGGCTTTGGAC-30, 50-TGGGCATGGCTGCATAG
ACT-50 and 50-TCAGAACCCACAAGCCCAGA-30, 50-AGGAATGGAGGC
AGCTGAGG-30.
2.10. Statistical analysis
Statistical signiﬁcance was evaluated using an unpaired two-
tailed t test or Anova test for siRNA experiments. Data are ex-
pressed as means ± standard error and differences were considered
as signiﬁcant (P < 0.05; ⁄); very signiﬁcant (P < 0.005; ⁄⁄) and highly
signiﬁcant (P < 0.001; ⁄⁄⁄).siCTR
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0.4 mM
89
BSA/NaOH
Palmitate 0.4 mM
BSA Palmitate
0.0
0.5
1.0
1.5
siCtr
siZBP-89
***
R
el
at
iv
e 
pr
ot
ei
n 
qu
an
tif
ic
at
io
n
**
palmitate for 24 h. Cells were transfected with nontargeted or ZBP89 siRNA prior to
antify Nur77 gene expression using Taqman probes. Quantiﬁcation represents three
C. Mazuy et al. / FEBS Letters 587 (2013) 3883–3890 38873. Results
3.1. Nur77 promoter activity is regulated by palmitate in MIN6 cells
To deﬁnewhether free fatty acids regulation ofNur77 expression
canbeascribed to itspromoter,weﬁrst investigated theeffect of pal-
mitate on a promoter fragment of 2000 bp cloned in pGL3TK-luc
vector. As shown in Fig. 1A, increasing concentration of palmitate
enhanced Nur77 promoter activity in a dose-dependant manner in
MIN6 pancreatic beta-cells. Higher concentrations of palmitate up
to 0.4 mMprovide amaximumstimulation (2.3-fold comparedwith
control) of Nur77 promoter in a physiological range of plasma free
fatty acid concentrations. The up-regulation (2.8-fold induction)
was also observed with the monounsaturated fatty acid oleate. We
conclude that saturated or unsaturated free fatty acids induce
Nur77 promoter activity. To delineate further the promoter regionSp1
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Fig. 5. (A and B) Conﬁrmation of Sp1 knockdown using MIN6 cells treated with 0.4 mM
mRNA extraction and qRT-PCR (A) or Western blot analysis (B). (C) Same cells were used
three independent experiments. Data are means ± S.D. (Student’s t-test).involved in the response to free fatty acids, we performed reporter
assay experiments using progressively shorter promoter constructs
(Fig. 1B). These experiments identiﬁed the region comprised be-
tween1668 and1445 bp upstream from the transcriptional start
site as essential for palmitate-mediated Nur77 promoter activation.
A search for transcription factor bindingmotifs usingMatInspec-
tor (www.genomatix.de) within the identiﬁed palmitate-respon-
sive region of the Nur77 promoter identiﬁed a ZBP89 binding site
overlapping a Sp1 binding site at 1534/1512 bp. To investigate
the relative function of these two factors, we ﬁrst introduced a
mutation in the Sp1/ZBP89 binding motif between 1525 and
1523 bp from transcription start (Fig. 2A). Potential Sp1 and
ZBP89 binding sites could not be individually mutated as they
strongly overlap. The introduced mutation had a drastic effect, as
the mutated promoter exhibited a 95% decreased activity in re-
sponse to palmitate compared to control (Fig. 2B).siCTR
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Sp1 binding to the Nur77 promoter
ChIP assays using MIN6 cells treated or not with palmitate were
performed to monitor ZBP89, Sp1 and RNA pol II binding to the
identiﬁed palmitate-responsive region within the Nur77 promoter
(Fig. 3). PCR ampliﬁcation of immunoprecipitated DNA revealed an
enhanced recruitment of RNA pol II in the presence of palmitate in
line with Nur77 transcriptional induction by palmitate [12]
(Fig. 3B). This was correlated with an increase in Sp1 binding
(6.4-fold increase) and a concomitant loss of ZBP89 recruitment
(Fig. 3A).
3.3. Activation of Nur77 promoter by palmitate is modulated by ZBP89
and Sp1
To investigate the role of ZBP89 and Sp1 in regulating Nur77
expression, we used a siRNA-based approach. ZBP89 expression
was down-regulated in MIN6 cells, by 50% (Fig. 4A), whereas the
control siRNA showed an unaltered ZBP89 expression. Western
blot analysis conﬁrmed the decreased expression level of ZBP89
protein (Fig. 4B). Nur77 mRNA expression was upregulated in
ZBP89-depleted MIN6 cells treated with 0.4 mM palmitate for
24 h to a higher extent than in control cells as shown in Fig. 4C.
The loss of ZBP89 expression potentiated activation of Nur77 tran-
scription by about 50% in response to palmitate. Thus, ZBP89 acts
as a repressor of the Nur77 promoter by binding to the identiﬁed
activation cassette. A similar approach was applied to Sp1. Using
a siRNA targeting Sp1 (Fig. 5A and B), we observed a decreased re-
sponse of Nur77 gene expression (Fig. 5C) after palmitate stimula-
tion. The functional signiﬁcance of these interactions was tested in
a transactivation assay, in which Nur77 promoter fragments were
cotransfected with ZBP89 or Sp1 expression vectors (Fig. 6). Palmi-
tate enhanced Nur77 promoter activity (2.5-fold compared with0
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mut), with a ﬁxed amount of an expression vector coding either for ZBP89 or Sp1.
Luciferase activity was assayed after 24 h palmitate treatment. Quantiﬁcation
represents three independent experiments. Data are means ± S.D.control) in the presence of an empty expression vector. ZBP89
overexpression abolished the Nur77 promoter response to palmi-
tate, whereas overexpression of Sp1 increased palmitate-induced
Nur77 promoter activity (3.7-fold compared with control) and gene
expression level (data not shown). In contrast, coexpression of
ZBP89 or Sp1 had no effect on Nur77 induction of the mutated,
non palmitate-responsive promoter fragment. In conclusion, these
results show that ZBP89 and Sp1 modulate Nur77 gene expression
upon palmitate treatment. Thus, we propose that the palmitate-in-
duced activation of the Nur77 promoter activity is linked to Sp1
recruitment and concommitant ZBP89 release potentially through
direct competitive binding to the promoter (Fig. 7).4. Discussion
As extracellular signals induce NR4A receptors in a context- and
cell type-dependent manner, the target genes and functions of
NR4A receptors are also likely to be tissue-and context-dependent.
Several transcription factors have been shown to regulate Nur77
promoter activity like b-catenin, which binds to AP-1 binding sites
in the Nur77 promoter [14] in colon cancer cells or C/EBPb, which
cooperates with the p50 subunit of NF-jB to further enhance
Nur77 promoter activity in Leydig cells [15]. The NF-jB signaling
pathway was identiﬁed as regulating Nur77 expression, whose pro-
moter harbors two highly conserved NF-jB response elements in
macrophages [16]. It was also known that Nur77 promoter is con-
trolled by CREB protein (c-AMP response element binding protein)
in PC12 cells [17] and MEF2 protein in T-cells [18]. Although Nur77
up-regulation is a marker of cellular stress in cultured insulinoma
b-cells, how fatty acids induce Nur77 expression remains unclear.
We recently reported an increase in Nur77 expression in b-pancre-
atic cell lines and in isolated human pancreatic islets upon expo-
sure to the saturated FA palmitate. This increased expression of
Nur77 induced an inhibition of insulin biosynthesis through mafA
expression [12]. In this report, we provide mechanistic bases for
the fatty acid-induced activation of Nur77 in pancreatic b-cells at
physiological concentration of 0.4 mM.
Using transactivation assays with Nur77 promoter deletion con-
structs, we identiﬁed a regulatory region within the Nur77 pro-
moter between 1668 and 1445 bp from the transcriptional
start responsible for pancreatic b-cells Nur77 promoter activation
by palmitate. An activation cassette with an overlapping ZBP89/
SP1 binding site was identiﬁed as a potential candidate by se-
quence comparison with a transcription factor binding site
database (Matinspector). Indeed, a mutation in this activation cas-
sette had a strong effect on palmitate-induced Nur77 promoter
activity. Although ubiquitous, ZBP89 is a Krüppel-type zinc ﬁnger
protein not only expressed in T-cells [19,20], but also in normal hu-
man pancreatic islets and insulinomas cells [21]. ZBP89 regulates
diverse biological functions through direct promoter binding as
well as through protein–protein interactions. In addition, ZBP89
regulates cell growth by inhibiting cell proliferation [22,23] and
induces apoptosis in human cells [24]. This protein binds a GC-rich
responsive element from several promoters like collagen [25]; b-
enolase [26] or vimentin [27]. ZBP89 has bifunctional regulatory
domains suggesting that it may function as both a transcriptional
activator and repressor. ZBP89 inhibits cell growth via the repres-
sion of gastrin and ornithine decarboxylase [25,26]. More recently,
[28] revealed that neuronal insulin receptor substrate 2 (IRS2)
expression is regulated by ZBP89 and Sp1 binding to the IRS2
promoter. A regulatory cassette composed of four ZBP89/SP1 bind-
ing sites controlled the IRS2 promoter activity in response to the
PI3K pathway activation. Similarly, our chromatin immunoprecip-
itation assay conﬁrmed the speciﬁc DNA binding of ZBP89 and Sp1
on the described region in the Nur77 promoter. Treatment with
Nur77 promoter
-1-2000
SP1
-1525/23
Fatty acids
Nur77 promoter
-1-2000
ZBP89
-1525/23
ZBP89
Fig. 7. Regulation of Nur77 promoter activation by fatty acid exposure: an alternative binding of ZBP89 and Sp1.
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identiﬁed sequence, while a complete loss of ZBP89 DNA binding
activity was observed. Palmitate is known to induced Sp1 DNA
binding to a Sp1 consensus sequence indicative of an increased
activity of this transcription factor [29]. This binding activity may
be mediated by enhanced O-GlcNac modiﬁcation through the hex-
osamine pathway.
To understand the inﬂuence of ZBP89 and Sp1 binding to the
Nur77 promoter, we used knockdown experiments using siRNA.
Without changing Sp1 expression, we performed palmitate stimu-
lation using MIN6 cells transfected with siRNA against ZBP89. In
this condition, ZBP89 repressed palmitate-induced Nur77 gene
expression in MIN6 cells. In contrast, Sp1 knockdown decreased
Nur77 gene expression indicating that Sp1 could promote Nur77
gene expression induction by palmitate. All these results showed
that a differential binding of ZBP89 and Sp1 could regulate Nur77
promoter activity. Consequently, we assumed that the regulation
of promoter activity might be controlled via a competitive binding
of the two proteins to overlapping binding sites. Interestingly, di-
rect competitive binding of ZBP89 and Sp1 to a shared DNA binding
sequence has also been implicated into regulation of the ODC gene
promoter activity [30]. As Nur77 stimulates glucose production
[31] and decreased pancreatic b-cell insulin secretion [12], a func-
tional interaction could be involved in metabolic regulation.
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